Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Hailin, Ding"'
Autor:
Feixiang Xu, Xiao Tan, Jianli Wang, Su Lu, Hailin Ding, Mingming Xue, Yumei Chen, Sheng Wang, Jie Teng, Yiqin Shi, Zhenju Song
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Background Sepsis-induced acute kidney injury (S-AKI) is a common complication in critically ill patients. Therefore, reliable biomarkers for predicting S-AKI outcomes are necessary. Serum cell-free DNA (cfDNA) is a circulating extracellular DNA frag
Externí odkaz:
https://doaj.org/article/709c01c338f5446e8a835a51510c5461
Autor:
Mengna Lin, Kangli Cao, Feixiang Xu, Xueling Wu, Yao Shen, Su Lu, Zhongshu Kuang, Hailin Ding, Shuyun Yuan, Mian Shao, Guorong Gu, Lingyu Xing, Tianwen Gu, Shaodie Chen, Jian Sun, Jiamin Zhu, Xiaoyan Zhang, Yilin Yang, Guoping Zhao, Lihong Huang, Jianqing Xu, Zhenju Song
Publikováno v:
Emerging Microbes and Infections, Vol 12, Iss 2 (2023)
Limited follow-up data is available on the recovery of Omicron COVID-19 patients after acute illness. It is also critical to understand persistence of neutralizing antibody (NAb) and of T-cell mediated immunity and the role of hybrid immunity in prev
Externí odkaz:
https://doaj.org/article/b7dbcfcb3b0b4f78af5ef76642eecce4
Autor:
Hua Zhang, Ting Chen, Vamsidhar Velcheti, Kwok-Kin Wong, Jared E Lopes, Heather C Losey, Elaine Shum, Han Han, Hai Hu, Yuanwang Pan, Yuan Hao, Hailin Ding, Kristen E Labbe, Kayla Guidry, Fiona Sherman, Ke Geng, Janaye Stephens, Alison Chafitz, Sittinon Tang, Hsin-Yi Huang, Chengwei Peng, Christina Almonte, Raymond J Winquist
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less than 7%. The addition of immunotherapy to chemotherapy was recently approved as first-line treatment; however, the improved clinical benefit is modest, highli
Externí odkaz:
https://doaj.org/article/5f4845cac4494148a2dafe15454c9d88
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
GSEA analysis of mobocertinib and T-DM1 treated tumors versus mobocertinib-only treated tumors Genes involved in "INTERFERON ALPHA RESPONSE", "INFLAMMATORY RESPONSE", "INTERFERON GAMMA RESPONSE", "IL2 STAT5 SIGNALING", "TNFA SIGNALING VIA NFKB" and "
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc292ba115983e2e9d41bf0078c4067
https://doi.org/10.1158/0008-5472.22490195
https://doi.org/10.1158/0008-5472.22490195
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3282ae56d3b65e02abbca4ecf45fe434
https://doi.org/10.1158/0008-5472.c.6533114
https://doi.org/10.1158/0008-5472.c.6533114
Autor:
Kwok-Kin Wong, Sylvie Vincent, Rachael Brake, Victor M. Rivera, Haiquan Chen, Francois Gonzalvez, Sittinon Tang, Eleni Papadopoulos, Cassandra Thakurdin, Val Pyon, Hai Hu, Hailin Ding, Yuanwang Pan, Hua Zhang, Fei Li, Theresa E. Baker, Zhendong Gao, Jiehui Deng, David Peng, Jiansheng Wu, Johara Chouitar, Shougen Cao, Kwan Ho Tang, Chengwei Peng, Shengwu Liu, Michael Fitzgerald, Ting Chen, Shuai Li, Han Han
Figure S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b801af9cd01bb649be8ad1b6d441cd
https://doi.org/10.1158/0008-5472.22490216
https://doi.org/10.1158/0008-5472.22490216
Autor:
Zhiyin Wang, Dan Liu, Yimin Dai, Ruotian Li, Yaowu Zheng, Guangfeng Zhao, Jingmei Wang, Zhenyu Diao, Chenrui Cao, Haining Lv, Ning Gu, Hang Zhou, Hailin Ding, Jie Li, Xiangyu Zhu, Honglei Duan, Li Shen, Qun Zhang, Jing Chen, Huilian Hu, Xiaoyan Wang, Mingming Zheng, Yan Zhou, Yali Hu
Publikováno v:
Hypertension (Dallas, Tex. : 1979).
Background: Preeclampsia is a complicated syndrome with marked heterogeneity. The biomarker-based classification for this syndrome is more constructive to the targeted prevention and treatment of preeclampsia. It has been reported that preeclamptic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8faa5b780333c0a37af92aa86d80501
https://pubmed.ncbi.nlm.nih.gov/36519433
https://pubmed.ncbi.nlm.nih.gov/36519433
Autor:
Yi Han, Mengna Lin, Feixiang Xu, Keyu Sun, Bin Yang, Su Lu, Hailin Ding, Jianli Wang, Guorong Gu, Min Min, Zhongshu Kuang, Mingming Xue, Lingyu Xing, Yunqiang Zhang, Huifang Liu, Weibing Wang, Yun Zhang, Chaoyang Tong, Hong Zhang, Zhenju Song
Background: The lung microbiota and host immune response is thought to be a key player in the progression of pneumonia. However, the critical features of the microbiota have rarely been studied in severe community-acquired pneumonia (SCAP) patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd88ca2efda8b26eed9eded8861bbcfc
https://doi.org/10.21203/rs.3.rs-2182064/v1
https://doi.org/10.21203/rs.3.rs-2182064/v1
Autor:
Hua Zhang, Haiquan Chen, Sittinon Tang, Shougen Cao, Yuanwang Pan, Victor M. Rivera, Shuai Li, Fei Li, Kwan Ho Tang, Hai Hu, Chengwei Peng, Francois Gonzalvez, Hailin Ding, Jiehui Deng, Johara Chouitar, Han Han, Sylvie Vincent, Theresa E. Baker, Michael Fitzgerald, Val Pyon, Ting Chen, Zhendong Gao, Rachael L. Brake, Eleni Papadopoulos, David H. Peng, Jiansheng Wu, Cassandra Thakurdin, Kwok-Kin Wong, Shengwu Liu
Publikováno v:
Cancer Research. 81:5311-5324
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f7997759bba1b98f3f10b2c5af242a6
https://doi.org/10.1158/0008-5472.can-21-1526
https://doi.org/10.1158/0008-5472.can-21-1526
Autor:
Yuanwang Pan, Yuan Hao, Han Han, Ting Chen, Hailin Ding, Kristen E Labbe, Elaine Shum, Kayla Guidry, Hai Hu, Fiona Sherman, Ke Geng, Janaye Stephens, Alison Chafitz, Sittinon Tang, Hsin-Yi Huang, Chengwei Peng, Christina Almonte, Jared E Lopes, Heather C Losey, Raymond J Winquist, Vamsidhar Velcheti, Hua Zhang, Kwok-Kin Wong
Publikováno v:
Journal for immunotherapy of cancer. 10(9)
BackgroundSmall cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less than 7%. The addition of immunotherapy to chemotherapy was recently approved as first-line treatment; however, the improved clinical benefit is modest, highlig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d066777967055bb157d69269f541db5b
https://pubmed.ncbi.nlm.nih.gov/36472839
https://pubmed.ncbi.nlm.nih.gov/36472839